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Crohn’s disease (CD) and ulcerative colitis (UC) challenge economies worldwide. Detailed
health economic data of DRG based academic inpatient care for inflammatory bowel dis-
ease (IBD) patients in Europe is unavailable.
Methods
IBD was identified through ICD-10 K50 and K51 code groups. We took an actual costing
approach, compared expenditures to G-DRG and non-DRG proceeds and performed
detailed cost center and type accounting to identify coverage determinants.
Results
Of all 3093 hospitalized cases at our department, 164 were CD and 157 UC inpatients in
2012. On average, they were 44.1 (CD 44.9 UC 43.3 all 58) years old, stayed 10.1 (CD 11.8
UC 8.4 vs. all 8) days, carried 5.8 (CD 6.4 UC 5.2 vs. all 6.8) secondary diagnoses, received
7.4 (CD 7.7 UC 7 vs. all 6.2) procedures, had a higher cost weight (CD 2.8 UC 2.4 vs. all
1.6) and required more intense nursing. Their care was more costly (means: total cost IBD
8477€ CD 9051€ UC 7903€ vs. all 5078€). However, expenditures were not fully recovered
by DRG proceeds (means: IBD 7413€, CD 8441€, UC 6384€ vs all 4758€). We discovered
substantial disease specific mismatches in cost centers and types and identified the medi-
cal ward personnel and materials budgets to be most imbalanced. Non-DRG proceeds
were almost double (IBD 16.1% vs. all 8.2%), but did not balance deficits at total coverage
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analysis, that found medications (antimicrobials, biologics and blood products), medical
materials (mostly endoscopy items) to contribute most to the deficit.
Conclusions
DRGs challenge sophisticated IBD care.
Introduction
Due to their increasing incidence and early age peaks in the 2nd and 3rd decade and commonly
associated extraintestinal manifestations the systemic conditions Crohn’s disease[1] (CD) and
ulcerative colitis[2] (UC) substantially impact on patient’s personal and professional lives and
challenge economies and healthcare systems worldwide. The complete economic burden has
been estimated at 8.1 to 14.9 for UC and 10.9 to 15.5 billion US$ for CD, respectively in the
United States and 12.5 to 29.1 for UC and 2.1 to 16.7 billion € for CD annually in Europe[3, 4].
Several countries in Europe[5–7], North America[8, 9] and Australia[10] have decided to
introduce diagnosis related group (DRG) billing systems hoping to achieve better cost control.
The origins of the DRG system date back to a collaborative project at the Yale University
School of Management and School of Public Health[11]. European DRG systems have imple-
mented different design options, are generally more detailed than the Medicare DRG system
aiming to better distinguish among patients with less and more complex conditions and
include physician salaries and re-admission[12]. DRG was introduced as a MeSH term in
PubMed in 1991.
DRG introduction, an overall very low investment ratio in hospitals and passing of Euro-
pean Union legislation[13] that dictates a strict separation of business (i.e. hospital) from non-
business (i.e. academic) activities put most academic medical centers into financial turmoil[6,
14]. This resulted in extreme scrutiny towards medical specialties caring for cost intensive
patients.
It is currently unknown, if and how actual expenses are distributed and balanced with DRG
proceeds in inflammatory bowel disease (IBD) inpatients at academic medical centers.
Methods
The aim of our study was to compare actual cost and revenue with respective DRG proceeds
for IBD cases and relate them to all other gastroenterology and hepatology inpatient cases
within the same period. Moreover, we wanted to identify and analyze factors contributing to
either excess (DRG proceeds higher than actual costs) or deficit (DRG proceeds lower than
actual costs) coverage in IBD cases.
Data source and identification of cases
All data were extracted from our medical center’s data warehouse running SAP NetWeaver
Business Intelligence software[15] and other IT systems. In full conformity with all applicable
federal privacy rules and regulations, no personally identifiable information was collected.
From all inpatient service cases seen in 2012 at our department we identified inflammatory
bowel disease patients using the German modification (ICD-10-GM)[16] of the WHO ICD-10
[17] code groups for Crohn’s disease (K50) and ulcerative colitis (K51). Coding at out medical
center is primarily done by specialized nurses and confirmed by physicians. No additional veri-
fication was performed for this research study. Data sets included age, gender, ICD-10-GM[16]
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coded main and secondary diagnoses, length of stay, procedures coded by the German modifi-
cation (OPS)[18] of the International Classification of Health Interventions (ICHI)[19] and
G-DRG, patient clinical complexity level (PCCL) [20]), cost weight (CW)[21], length of stay
and discharge type.
Calculation basis and accounting
All calculations were based on national coding rules[22] of the German Institute for the Hospi-
tal Remuneration System (InEK). The allocation of costs to a case followed a full-cost approach
based on actual cost. Included were all cases, benefits and costs of the hospital under the remu-
neration framework of the G-DRG[23] system. The 2012 grouper (software to calculate diag-
nosis related groups–DRGs) and a base rate of € 2,985 were applied.
Cost type accounting. Prior to cost type accounting data were adjusted to exclude non-
DRG relevant positions (e.g. other periods, extraordinary expenses or investments). Further-
more, all accounts were delineated for services compensated outside of the DRG system and
those serving primary scientific research and teaching of medical students to meet EU aca-
demic accounting rules that prohibit subsidizing medical care through academic activities[13].
Cost center accounting—Cost centers were initially divided in direct (immediate patient
care) and indirect (e.g. administration, facility management) cost centers. The settlement was
based on the calculation set out in national coding guidelines[22] employing the equation
method.
Cost unit accounting. Finally, the allocation of the costs of direct cost centers was carried
out on an individual case basis and in the K50 and K51 case groups. Allocations were based on
cost type- and center benchmarks. Direct costs were added to the cases based on information
from the hospital information system (HIS) on used material costs, medications, medical imaging
and operating room expenses. All other costs not fitting these categories (overheads) were distrib-
uted and added according to performance keys (e.g. operating roomminutes, length of stay).
Results
Patient population
A total of 3093 individuals received full spectrum academic gastroenterology and hepatology
inpatient care at our department in 2012. We identified 321 cases with inflammatory bowel dis-
ease. Table 1 summarizes their demographics and key economic Figures. At a glance, IBD
patients were on average fifteen years younger, stayed two (UC) to three days (CD) longer on
their admissions, were sicker (CD> UC), required more intense nursing (CD> UC), received
one to two more procedures (CD> UC) and generated almost twice the total cost compared
with the average inpatient. The care of CD patients was more costly compared with UC and
the average of all inpatients, but overall resulted in an excess coverage when DRG and non-
DRG proceeds were included.
Crohn’s Disease–main and secondary diagnoses, procedures and
DRGs
All 164 Crohn’s disease patients were grouped into 9 main DRG categories (Fig 1) and 33
actual DRGs (S1 Table).
This grouper assignment was based on 29 main diagnoses (S2 Table), 388 distinct second-
ary diagnoses (S3 Table) of and 167 distinct procedures (S4 Table).
In most patients (n = 129 78.66%) a Crohn’s disease ICD-10 code (K50.0 group) was
selected as the main (i.e. discharge) diagnosis indicating admission for actual worsening of
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their illness. The list of secondary diagnoses shows that many patients were immunosup-
pressed, screened and treated for opportunistic infections or experienced other complications
Table 1. Summary of key demographic and health economic Figures of inflammatory bowel disease cases versus all gastroenterology and hepa-
tology academic inpatient service cases in 2012 calculated with a base rate of € 2985.
Crohn‘s Disease Ulcerative Colitis IBD All
Mean ∑ Mean ∑ Mean ∑ Mean ∑
N 164 157 321 3,093
Age [years] 44.9 43.3 44.1 58
Length of stay [days] 11.8 1,928 8.4 1,321 10.1 1,625 8 24,615
Cost Weight (CW) 2.828 464 2.139 336 2.4835 400 1.594 4930
PPR (Nursing Effort) 1,516 256,058 909 142,758 1,213 199,408 1,029 3,182,588
No. of Secondary Diagnoses 6.4 5.2 5.8 6.8
No. of Procedures 7.7 7 7.35 6.2
Total Costs [€] 9,051 1,484,367 7,903 1,240,767 8,477 1,362,567 5,078 15,704,871
Daily Costs [€] 770 126,264 946 148,476 858 13,370 638 1,973,397
DRG Proceeds [€] 8,441 1,384,389 6,384 1,002,238 7,413 1,193,314 4,758 14,716,422
Other Proceeds [€] 1,241 203,406 1,611 252,965 1,426 228,186 426 1,318,951
Total Revenue [€] 9,684 1,588,096 7,995 1,255,203 8,840 1,421,650 5,184 16,035,373
Cover [€] 632 103,728 92 14,436 362 59,082 107 330,501
Coverage [%] 7 1 4 2
doi:10.1371/journal.pone.0147364.t001
Fig 1. Crohn’s Disease: Major DRG categories sorted by case frequency and stratified by cost weight (CW) and coverage.
doi:10.1371/journal.pone.0147364.g001
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of their disease and treatment such as diarrhea induced hypokalemia, intestinal obstruction,
fistulas, urinary tract infections, bleeding anemia, and required surgery, central line placement
or isolation for contamination with multiresistant pathogens. The most commonly performed
procedures were endoscopies with biopsies mostly in intravenous anesthesia, pelvic and
abdominal MRIs or CTs with contrast, the administration of biologics and other immune ther-
apies, surgical procedures including fistula seton placement, transfusions of various blood
products as well as central line placement. The large number of almost 400 different secondary
diagnoses along with 167 distinct procedures and interventions performed is consistent with
the diverse nature and course of Crohn’s disease itself, its generally higher number of associated
extraintestinal manifestations[24, 25] and the tertiary care type of setting in our center. The
medical complexity of these cases is only partly reflected in the DRGs calculated by the grouper
software, which defines cost weight largely by invasive procedures and critical care. The major-
ity of cases fell into deficient DRGs. Fig 1Our analysis demonstrates that only cases that
required an endoscopy or were admitted to the ICU were profitable, while those assigned to
native gastroenterology DRGs were not. The excess coverage of critical care and particularly
mechanical ventilation plus non-DRG proceeds eventually generated an overall positive mean
cover statement of +7%. Table 1
Crohn’s disease–comprehensive cost and revenue analysis
Actual costs. The analysis of the mean actual costs (9051€) (S5 Table) shows that on aver-
age most expenditures were accrued in the medical ward, intensive care unit and laboratory
cost centers and spent for personnel (3982€), followed by materials (including medications)
(2999€) and for infrastructure (2070€).
Within personnel expenses for nursing care of Crohn’s patients exceeded compensation for
physicians, while in the materials section medications and in the infrastructure section non-
medical infrastructure costs (administrative overhead, utilities, short-term maintenance, soft-
ware licenses etc.) dominated.
DRG Proceeds. The mean actual costs of Crohn’s disease care (9051€) were not balanced
by mean DRG proceeds (8441€) (S6 Table). There was a substantial mismatch between major
cost centers and types. While the DRG overall personnel coverage of 4665€ exceeded the actual
expenses, the budget for personnel expenses on the medical ward fell fifty percent short and
exceeded the actual expenses on the intensive care unit. There was also a major gap in materials
coverage (including medications) (1610€). Infrastructure costs (2176€) appeared overall bal-
anced, but a closer look revealed a mismatch here too.
Non-DRG Proceeds. The detected mismatch, especially in the personnel budget of the
ICU and medical ward and the non-medical infrastructure was not compensated with extra 34
€ and 8€ respectively of non-DRG proceeds as these are mainly meant to cover novel medica-
tions, diagnostic tests and procedures (1200€). S7 Table
Total Coverage. In a comparison of actual costs with DRG proceeds plus non-DRG pro-
ceeds, the most deficient cost centers remain the medical ward, operating room, imaging and
anesthesia, while the ICU generated the largest excess coverage. Fig 2
At cost type level, the largest excess coverage was observed in the (ICU) nursing budget,
whereas individual medication and material costs and non-medical infrastructure costs con-
tributed the most to the deficit. Fig 3.
Ulcerative colitis–main and secondary diagnoses, procedures and DRGs
All 157 ulcerative colitis patients were grouped into 13 main DRG categories (Fig 4) and 28
actual DRGs (S8 Table).
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This grouper assignment was based on 31 main diagnoses (S9 Table), 295 distinct second-
ary diagnoses (S10 Table) and 225 distinct procedures (S11 Table).
In half of the patients (n = 77 49.04%) an ulcerative colitis ICD-10 code (K51 group) was
selected as the main (i.e. discharge) diagnosis, in more than a third (n = 53 33.75%) a (primary
sclerosing) cholangitis ICD-10 code (K83 K81 groups) and in 7.64% of cases (n = 12) another
liver (including transplant) problem related ICD-10 code (K74, K76, T86 groups). This indi-
cates that 98.49% of patients were admitted for either their UC or a UC related liver problem.
The list of secondary diagnoses shows that many patients were immunosuppressed and
developed infections, came in for primary sclerosing cholangitis (PSC) related issues including
evaluation for or status post liver transplantation, required screening and treatment for oppor-
tunistic infections or experienced other complications of their disease and treatment such as
bleeding anemia, iron deficiency anemia, coagulation problems, surgery or isolation for con-
tamination or infection with multiresistant pathogens.
The most commonly performed procedures were upper and lower endoscopies as well as
hepatobiliary interventions in mostly intravenous anesthesia (including papillotomy, biliary
balloon dilation, biliary stenting, biopsies and cytology, and variceal banding), abdominal, pel-
vic MRI and CT or MRCP with contrast, the administration of biologics and other immune
therapies, transfusion of blood products as well as central line placement.
The large number of almost 300 different secondary diagnoses along with 225 distinct pro-
cedures and interventions performed is consistent with the tertiary care type of setting of our
institution which is also the nation’s highest volume visceral transplant center.
The medical complexity of these cases is better reflected in the DRGs calculated by the grou-
per software, which defines cost weight largely by invasive procedures such as ERCP and criti-
cal care than in Crohn’s disease. Most cases fell into fairly well covered DRGs. The DRG
Fig 2. Crohn’s Disease: Cost center based total coverage analysis. Bars denote mean excess or deficit.
doi:10.1371/journal.pone.0147364.g002
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coverage distribution was more even than in Crohn’s disease with fewer extremes. Fig 5 dem-
onstrates that cases requiring an endoscopy or affected the hepatobiliary system were profit-
able, while those assigned to digestive surgery DRGs or DRGs with malignancy were highly
deficient. The excess coverage of hepatobiliary and complex endoscopy cases plus non-DRG
proceeds eventually generated an overall positive mean cover statement of +2%. Table 1
Ulcerative colitis–comprehensive cost and revenue analysis
Actual costs. The analysis of the mean actual costs (7903€) (S12 Table) shows that on
average most expenses were accrued in the medical ward, intensive care unit and laboratory
cost centers and were spent for personnel (3192€), closely followed by materials (including
medications) (3207€) and infrastructure costs (1502€).
Within personnel, the expenditures for nursing care of ulcerative colitis patients exceeded
those for physicians, whereas in the materials section medications and in the infrastructure sec-
tion non-medical infrastructure costs (administrative overhead) dominated. Of note, like in
Crohn’s disease more money was spent for non-medical infrastructure costs than for
physicians.
DRG-Proceeds. The mean actual costs of ulcerative colitis were not balanced by mean
DRG proceeds (6384€) (S13 Table). The mismatch was largely caused by insufficient coverage
of personnel costs on the medical ward and materials. This becomes even more obvious when
comparing DRG proceeds (1307€) and actual costs for materials which do not recover individ-
ual medications and medical materials expenditures.
Fig 3. Crohn’s Disease: Cost type based total coverage analysis. Bars denote mean excess or deficit.
doi:10.1371/journal.pone.0147364.g003
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Non-DRG Proceeds. The detected mismatch, was partly compensated by non-DRG mate-
rials (1431€) proceeds as these are mainly meant to cover novel medications, diagnostic tests
and procedures. (S14 Table).
Total Coverage. In a comparison of actual costs with DRG plus non-DRG proceeds, the
most deficient cost centers remain the medical ward, dialysis, anesthesia and endoscopy, while
the ICU generated a modest excess coverage. Fig 5 At cost type level, the largest excess cover-
age was generated through the medical infrastructure budget, whereas individual medication
and medical material costs contributed the most to the deficit. Fig 6
Relation of coverage to gender, patient complexity level (PCCL) and
length of stay
Relating coverage to length of stay, PCCL and gender revealed that very sick patients (PCCL
4), extended stays and female gender in CD as opposed to mild to moderately sick (PCCL 2
and PCCL 3) patients, short stays and female gender in UC were associated with excess cover-
age. Fig 7
Individual medications and materials analysis at single cost level
Individual medication (CD vs. UC: 514 vs. 449 distinct medication formulations) and medical
material (CD 324 vs. UC: 222 distinct medical materials) costs contribute second most to the
Fig 4. Ulcerative Colitis: Major DRG categories sorted by case frequency and stratified by cost weight (CW) and coverage.
doi:10.1371/journal.pone.0147364.g004
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expenditures of academic IBD inpatient care (S5 Table and S12 Table). The also make up
most of the remaining deficit in total coverage (Fig 1 and Fig 2). Thus, we looked at them in
Crohn’s disease (detailed data on file) and ulcerative colitis (detailed data on file) in more
detail.
Individual medical materials. In Crohn’s disease, the most expensive medical materials
were used for interventional endoscopy and radiology, critical care and dialysis as well as medi-
cal imaging (CT and MRI contrast agents) (detailed data on file). In ulcerative colitis, the
expenditure distribution was comparable with additional spending for artificial extracorporeal
liver support.
Individual medications. In Crohn’s disease anti-TNF biologics, packed red blood cells
and antifungals are the three most expensive medications, while in ulcerative colitis antifun-
gals, platelets and anti-TNF biologics lead (detailed data on file). These lists once again illus-
trate the severity of the illness of academic IBD inpatients who are obviously admitted with
severe and often opportunistic infections frequently requiring the use of reserve antimicrobials
including potent anti-fungal drugs, transfusion of blood products, parenteral nutrition or
enteral nutrition supplementation and biologics.
Discussion
This is the first and currently only comprehensive and highly detailed analysis of IBD inpatient
care costs and revenues in a European DRG based healthcare system.
We show that IBD inpatients are on average more severely ill than their fellow inpatients as
indicated by admissions for mostly life threatening complications of their disease such as ful-
minant flares, infections with multiresistant and/or opportunistic pathogens, acute bleeding
and coagulation disorders, longer stays, requirement of more intense nursing and critical care,
Fig 5. Ulcerative colitis: Cost center based total coverage analysis. Bars denote mean excess or deficit.
doi:10.1371/journal.pone.0147364.g005
Health Economics of IBD in Academic Medicine
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Fig 6. Ulcerative Colitis: Cost type based total coverage analysis. Bars denote mean excess or deficit.
doi:10.1371/journal.pone.0147364.g006
Fig 7. Relation of mean total coverage to gender, patient complexity level (PCCL) and length of stay
stratified by Crohn’s disease and ulcerative colitis.
doi:10.1371/journal.pone.0147364.g007
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dependence on expensive cross sectional imaging studies with contrast agents, interventional
endoscopy, blood products, immune therapies including biologics and special medical materials.
Thus, perhaps not surprisingly the expenditures for their care are almost double of those for the
average academic gastroenterology inpatient. Moreover, our detailed analyses demonstrate that
costs, revenues, and their mismatch for Crohn’s disease and ulcerative colitis patients are distinct
in various cost type and cost center domains, reemphasizing that CD and UC are two different
systemic inflammatory disease groups, with Crohn’s being the most heterogeneous one.
We demonstrate that expenditures are not fully recovered by DRG proceeds. In extensive
coverage analyses we show, that particularly in Crohn’s disease, but also in ulcerative many
DRGs assigned by the grouper software result in coverage deficits. This is particularly true,
when IBD specific, rather than interventional procedure oriented DRGs are assigned. Cost cen-
ter and cost type analyses discovered particularly serious mismatches in in the personnel, labo-
ratory, single medication and medical materials budgets. Blood products, antimicrobial and
biologic drugs as well as interventional procedure and critical care related material costs con-
tribute substantially to the deficit. Somewhat surprisingly, more money is spent for non-medi-
cal infrastructure costs than for physicians. This does not seem to be disease specific though,
but rather relates to the size of the institution and a disproportional quota of controlling and
business vs. medical staff. Non-DRG generated proceeds were almost double that of the average
gastroenterology and hepatology inpatient (16.1% vs. 8.2%) and contribute to an overall posi-
tive cover statement for both UC and CD. A positive cover statement should not be confused
with a balanced cost and revenue distribution though, as our total coverage analyses conclude.
PCCL and length of stay have literally the opposite effects on total coverage in CD and UC,
while female gender appears to independently associated with greater revenues.
While several studies have theoretically modeled and estimated healthcare costs of IBD
patients [3, 4] [26], very few have investigated actualDRG data. In 1990, new incentives regard-
ing delivery of inpatient care by physicians and administrators have resulted fromMedicare's
DRG-based prospective reimbursement system in the US. A research study published that year
investigated the hypothetical application of the IBDMedicare DRG on 507 IBD inpatient admis-
sions (of which only 10.8% were actual Medicare cases) staying on average 9.71 days at a US
large tertiary care hospital and concluded inadequate reimbursement with an average theoretical
loss of 127.24 US$ which largely resulted from CD patients requiring surgery[27].
A Canadian study compared direct patient care costs between 1994 and 1995 based on
Canada’s DRG system[9] for medical and surgical IBD admissions. Surgical admissions were
more costly, especially when controlling for total parenteral nutrition. Interestingly, the non-
digestive DRG coded admissions, were more costly, which is the opposite of what we found,
probably because the G-DRG[23] grouper puts more weight on interventional procedures and
ICU care. However, regarding cost centers and cost types, the Canadian data is strikingly in
line with ours listing nursing, medications, labs, operating room, diagnostic imaging and
endoscopy as the top categories[28].
In their 2005 and 2006 data based case control study the same group compared also IBD with
non-IBD age and gender matched costs[29]. Our data can be partially related to the inpatient
portion of their study that compared 1089 IBD cases with 5279 controls within one Canadian
province. They reported a mean total cost (excluding administrative overheads, emergency room
visits and physician salaries) for IBD 13495 CAN$, CD 12940 CAN$, UC 14183 CAN$ and non-
IBD 12607 CAN$ respectively. Since their non-IBD inpatient population consisted of controls
from an entire health system irrespective of diagnosis and specialty no conclusions can be drawn
here. However, their report that medications and biologics again contributed largely to costs is in
line with our results. These finding are apparently independent of any coding related issues as
Canadian doctors are well aware of and properly use DRG coding in IBD[30].
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Our study has limitations. Due to its single center design and restriction to an academic
adult gastroenterology and hepatology department it may not fully reflect the situation in
other academic medical centers or patients cared for in other subspecialties, i.e. pediatric IBD
patients or IBD patients exclusively cared for in the surgery department or the situation in
community hospitals, which don’t carry the extra effort and expenses of transplant patients.
Although the German DRG system was derived and refined from the Australian DRG sys-
tem, which was modeled after the US Medicare DRG system, national specifics in healthcare
funding preclude the full extrapolation of numeric data and uncritical applicability of the
results to all other countries, which applies to virtually all health economic analyses pub-
lished to date. Owed to the data source and privacy legislation we were unable to phenotype
patients according to the Montreal classification[31], report their disease onset or disease
duration, individual medications, their medical and surgical history details or outpatient
encounters (where no DRG billing is applied in Germany), which also impact on their overall
all healthcare costs.
Moreover, DRGs and their reimbursement are not static. In fact, many countries annually
review and revise their DRGs to accommodate the continuous advance of the science, practice
and economics of medicine[32] [33]. Partial aspects of this process are reflected in our study.
The non-DRG proceeds include adjustments to balance the higher medication costs not cur-
rently covered by DRGs. However, science and practice advance much faster than the adminis-
tration and distribution of healthcare funds.
Future research needs to investigate the development of academic inpatient care costs and
revenues over time, study academic outpatient care costs and compare both to private and
community in- and outpatient care data. A multicenter setting at national level is highly desir-
able, but currently not feasible as access to reliable primary data is very complicated due to pri-
vacy legislation and political partisanship of different providers and payors.
DRGs were thought to improve efficiency because they provide incentives for hospitals to
limit the services per patient and to treat more patients, but also in (un)intended consequences,
such as reduced quality of care, preference for profitable cases (“cherry picking”), forced
patient transfers (“patient dumping”), and frequent readmissions[33]. Our data demonstrate,
that all native, non-procedure or critical care oriented IBD DRGs are still deficient, despite
their annual adjustment and creation of almost 40% new DRGs since their introduction in
2004. Academic medical centers like ours rightfully receiving and caring for these complex dis-
eases are taking an economic downturn, because even one of the most sophisticated and
refined DRG systems is still unable to address their trues needs and associated costs. Patient
“dumping” from other providers that refer patients to academic medical centers (who cannot
reject patients by law) when their DRGs are financially exhausted is an everyday reality and
applies to IBD. Patient organizations representing these and other rare conditions need to
encourage politicians, payors and hospital management organizations to act on this to avoid an
increasingly negative impact on the quality and availability of their well- deserved care.
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